慢性阻塞性肺疾病稳定期管理的几个新视点：2021版 GOLD指南解读

doi:10.16150/j.1671-2870.2021.01.006

摘要/Abstract

关键词: 慢性阻塞性肺疾病, 遗传因素, 稳定期, 全球倡议

中图分类号:

R563.3

李庆云, 孙娴雯. 慢性阻塞性肺疾病稳定期管理的几个新视点：2021版 GOLD指南解读[J]. 诊断学理论与实践, 2021, 20(01): 43-47.

参考文献 36

[1]	Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease[R/OL]. [2021-02-20]. http://gold-copd.html.
[2]	Wang C, Xu J, Yang L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study[J]. Lancet, 2018, 391(10131):1706-1717. doi: 10.1016/S0140-6736(18)30841-9 URL
[3]	Li X, Wu Z, Xue M, et al. Smoking status affects clinical characteristics and disease course of acute exacerbation of chronic obstructive pulmonary disease: a prospectively observational study[J]. Chron Respir Dis, 2020, 17:1479973120916184.
[4]	Dransfield MT, Kunisaki KM, Strand MJ, et al. Acute exacerbations and lung function loss in smokers with and without chronic obstructive pulmonary disease[J]. Am J Respir Crit Care Med, 2017, 195(3):324-330. doi: 10.1164/rccm.201605-1014OC URL
[5]	Sonnex K, Alleemudder H, Knaggs R. Impact of smoking status on the efficacy of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review[J]. BMJ Open, 2020, 10(4):e037509. doi: 10.1136/bmjopen-2020-037509 URL
[6]	Bai JW, Chen XX, Liu S, et al. Smoking cessation affects the natural history of COPD[J]. Int J Chron Obstruct Pulmon Dis, 2017, 12:3323-3328. doi: 10.2147/COPD.S150243 URL
[7]	Layden JE, Ghinai I, Pray I, et al. Pulmonary illness related to e-cigarette use in illinois and wisconsin-final report[J]. N Engl J Med, 2020, 382(10):903-916. doi: 10.1056/NEJMoa1911614 URL
[8]	Blount BC, Karwowski MP, Shields PG, et al. Vitamin E acetate in bronchoalveolar-lavage fluid associated with EVALI[J]. N Engl J Med, 2020, 382(8):697-705. doi: 10.1056/NEJMoa1916433 URL
[9]	Gotts JE, Jordt SE, McConnell R, et al. What are the respiratory effects of e-cigarettes?[J]. BMJ, 2019, 367:l5980.
[10]	Sharma A, Lee J, Fonseca AG, et al. E-cigarettes compromise the gut barrier and trigger inflammation[J]. Science, 2021, 24(2):102035.
[11]	Jia X, Zhou S, Luo D, et al. Effect of pharmacist-led interventions on medication adherence and inhalation technique in adult patients with asthma or COPD: a systema-tic review and meta-analysis[J]. J Clin Pharm Ther, 2020, 45(5):904-917. doi: 10.1111/jcpt.13126 URL
[12]	Willard-Grace R, Chirinos C, Wolf J, et al. Lay health coaching to increase appropriate inhaler Use in COPD: a randomized controlled trial[J]. Ann Fam Med, 2020, 18(1):5-14. doi: 10.1370/afm.2461 pmid: 31937527
[13]	van der Molen T, van Boven JF, Maguire T, et al. Optimizing identification and management of COPD patients- reviewing the role of the community pharmacist[J]. Br J Clin Pharmacol, 2017, 83(1):192-201. doi: 10.1111/bcp.13087 pmid: 27510273
[14]	Hesso I, Gebara SN, Kayyali R. Impact of community pharmacists in COPD management: Inhalation technique and medication adherence[J]. Respir Med, 2016, 118:22-30. doi: S0954-6111(16)30157-3 pmid: 27578467
[15]	Vitacca M, Paneroni M, Zampogna E, et al. High-flow oxygen therapy during exercise training in patients with chronic obstructive pulmonary disease and chronic hypoxemia: a Multicenter randomized controlled trial[J]. Phys Ther, 2020, 100(8):1249-1259. doi: 10.1093/ptj/pzaa076 URL
[16]	Rutkowski S, Rutkowska A, Kiper P, et al. Virtual reality rehabilitation in patients with chronic obstructive pulmonary disease: a randomized controlled trial[J]. Int J Chron Obstruct Pulmon Dis, 2020, 15:117-124. doi: 10.2147/COPD.S223592 URL
[17]	李庆云. 国外睡眠呼吸疾病家庭无创正压通气治疗指南及专家共识概述[J]. 中华结核和呼吸杂志, 2017, 40(9):660-662.
[18]	Wilson ME, Dobler CC, Morrow AS, et al. Association of home noninvasive positive pressure ventilation with clinical outcomes in chronic obstructive pulmonary disease: a systematic review and meta-analysi[J]. JAMA, 2020, 323(5):455-465. doi: 10.1001/jama.2019.22343 URL
[19]	Magdy DM, Metwally A. Effect of average volume-assured pressure support treatment on health-related quality of life in COPD patients with chronic hypercapnic respiratory failure: a randomized trial[J]. Respir Res, 2020, 21(1):64. doi: 10.1186/s12931-020-1320-7 URL
[20]	Mouronte-Roibás C, Leiro-Fernández V, Fernández-Villar A, et al. COPD, emphysema and the onset of lung cancer. A systematic review[J]. Cancer Lett, 2016, 382(2):240-244. doi: S0304-3835(16)30544-4 pmid: 27666776
[21]	Sanchez-Salcedo P, Berto J, de-Torres JP, et al. Lung cancer screening: fourteen year experience of the Pamplona early detection program (P-IELCAP)[J]. Arch Bronconeumol, 2015, 51(4):169-176. doi: 10.1016/j.arbres.2014.09.019 URL
[22]	Caramori G, Casolari P, Cavallesco GN, et al. Mechanisms involved in lung cancer development in COPD[J]. Int J Biochem Cell Biol, 2011, 43(7):1030-1044. doi: 10.1016/j.biocel.2010.08.022 pmid: 20951226
[23]	Houghton AM. Mechanistic links between COPD and lung cancer[J]. Nat Rev Cancer, 2013, 13(4):233-245. doi: 10.1038/nrc3477 pmid: 23467302
[24]	Celli BR. Chronic obstructive pulmonary disease and lung cancer: common pathogenesis, shared clinical challenges[J]. Proc Am Thorac Soc, 2012, 9(2):74-79. doi: 10.1513/pats.201107-039MS URL
[25]	Moyer VA; U.S.Preventive Services Task Force. Scree-ning for lung cancer: U.S. Preventive Services Task Force recommendation statement[J]. Ann Intern Med, 2014, 160(5):330-338.
[26]	Ashraf H, Saghir Z, Dirksen A, et al. Smoking habits in the randomised Danish Lung Cancer Screening Trial with low-dose CT: final results after a 5-year screening programme[J]. Thorax, 2014, 69(6):574-579. doi: 10.1136/thoraxjnl-2013-203849 URL
[27]	Suissa S, Dell'Aniello S, Gonzalez AV, et al. Inhaled corticosteroid use and the incidence of lung cancer in COPD[J]. Eur Respir J, 2020, 55(2):1901720. doi: 10.1183/13993003.01720-2019 URL
[28]	Leung JM, Yang CX, Tam A, et al. ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19[J]. Eur Respir J, 2020, 55(5):2000688. doi: 10.1183/13993003.00688-2020 URL
[29]	Maes T, Bracke K, Brusselle GG. COVID-19, asthma, and inhaled corticosteroids: another beneficial effect of inhaled corticosteroids?[J]. Am J Respir Crit Care Med, 2020, 202(1):8-10. doi: 10.1164/rccm.202005-1651ED URL
[30]	Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 UK patients in hospital with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol: prospec-tive observational cohort study[J]. BMJ, 2020, 369:m1985.
[31]	Hippisley-Cox J, Young D, Coupland C, et al. Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people[J]. Heart, 2020, 106(19):1503-1511. doi: 10.1136/heartjnl-2020-317393 pmid: 32737124
[32]	RECOVERY Collaborative Group, Horby P, Lim WS, et al. Dexamethasone in hospitalized patients with COVID-19[J]. N Engl J Med, 2021, 384(8):693-704. doi: 10.1056/NEJMoa2021436 URL
[33]	World Health Organization. Clinical management of COVID-19[R/OL]. Interim guidance. 2020-05-27[2021-02-20]. https://www.who.int/publications/i/item/clinical-mang ement-of-covid-19.
[34]	Dobesh PP, Trujillo TC. Coagulopathy, venous thromboembolism, and anticoagulation in patients with COVID-19[J]. Pharmacotherapy, 2020, 40(11):1130-1151. doi: 10.1002/phar.2465 URL
[35]	Malik P, Patel U, Mehta D, et al. Biomarkers and outcomes of COVID-19 hospitalisations: systematic review and meta-analysis[J]. BMJ Evid Based Med, 2020:bmjebm-2020-111536.
[36]	Bellani G, Laffey JG, Pham T, et al. Noninvasive ventilation of patients with acute respiratory distress syndrome. Insights from the LUNG SAFE Study[J]. Am J Respir Crit Care Med, 2017, 195(1):67-77. doi: 10.1164/rccm.201606-1306OC URL

慢性阻塞性肺疾病稳定期管理的几个新视点：2021版 GOLD指南解读

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 36

相关文章 15

编辑推荐

Metrics

本文评价

[1]	孙娴雯, 李庆云. 新型冠状病毒疫情时期的慢性阻塞性肺疾病管理策略——2022版慢性阻塞性肺疾病全球倡议解读[J]. 诊断学理论与实践, 2022, 21(01): 32-37.
[2]	李庆云, 孙娴雯. 细化稳定期COPD管理流程和随访策略：2020版GOLD指南解读[J]. 诊断学理论与实践, 2020, 19(04): 354-358.
[3]	陈宇清, 王铭杰, 朱东, 吕城坚, 陈萍. 稳定期Ⅱ、Ⅲ级慢性阻塞性肺疾病患者的气道阻力对呼出气流受限的影响分析[J]. 诊断学理论与实践, 2019, 18(04): 418-422.
[4]	周敏, 张秋蕊. 呼吸道、肠道微生物菌群对慢性阻塞性肺疾病的发病及治疗的影响[J]. 诊断学理论与实践, 2019, 18(03): 246-249.
[5]	李媛媛, 张舒, 曹波, 陆晓晔, 刘黎, 陈杰, 归茜, 徐欣晖, 吕利雄, 朱长清,. 几种感染性疾病中外周血T淋巴细胞亚群变化的检测及其临床意义研究[J]. 诊断学理论与实践, 2015, 14(04): 363-366.
[6]	李庆云, 过依,. 慢性阻塞性肺疾病急性加重评估及稳定期用药选择:慢性阻塞性肺疾病全球倡议2015解读[J]. 诊断学理论与实践, 2015, 14(03): 215-218.
[7]	陈宇清, 吕成坚, 周新, 朱东,. 合并限制性通气功能障碍对稳定期Ⅱ、Ⅲ级慢性阻塞性肺疾病患者运动能力的影响[J]. 诊断学理论与实践, 2012, 11(04): 387-390.
[8]	邓伟吾,. 丙型肝炎病毒感染与慢性呼吸道疾病关系的认识[J]. 诊断学理论与实践, 2011, 10(05): 397-400.
[9]	马冠华, 杨昆, 李敏, 叶亮, 万欢英,. 呼吸道合胞病毒感染对慢性阻塞性肺疾病急性加重期患者的影响[J]. 诊断学理论与实践, 2010, 9(05): 503-506.
[10]	梁丽, 马佳韵, 李庆云, 陈振和, 周敏,. 慢性阻塞性肺疾病合并阻塞性睡眠呼吸暂停低通气综合征的临床特征[J]. 诊断学理论与实践, 2009, 8(06): 612-615.
[11]	陈宇清, 周新, 朱东, 戴晓敏,. 稳定期Ⅱ、Ⅲ级慢性阻塞性肺疾病患者的吸气分数与呼吸肌力研究[J]. 诊断学理论与实践, 2007, 6(05): 409-411.
[12]	谢灿茂, 周宇麒,. 慢性阻塞性肺疾病急性加重的现代评价[J]. 诊断学理论与实践, 2006, 5(02): 106-108.
[13]	秦慧, 李燕芹, 刘斌, 赵旭霁, 查琼芳, 邹静, 陈燕,. 呼气负压技术检测呼气流速受限在慢性阻塞性肺疾病中的应用[J]. 诊断学理论与实践, 2006, 5(02): 116-119.
[14]	余健民,. 趋化因子和细胞黏附分子在呼吸系统疾病诊断中的应用[J]. 诊断学理论与实践, 2006, 5(02): 109-112.
[15]	时国朝,黄绍光. 无创正压通气应用的几个关键问题[J]. 诊断学理论与实践, 2005, 4(03): 248-250.